Note: You clicked on an external link, which has been disabled in order to keep your shopping session open.
|Tested species reactivity||Human|
|Host / Isotype||Rabbit / IgG|
|Immunogen||Synthetic peptide derived from the C-terminus of human PgR|
|Purification||Antigen affinity chromatography|
|Storage buffer||PBS, pH 7.6, with 1% BSA|
|Contains||<0.1% sodium azide|
|Storage Conditions||4° C, do not freeze|
|Tested Applications||Dilution *|
|Immunohistochemistry (Paraffin) (IHC (P))||1:200|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
Heat-mediated antigen retrieval is recommended prior to staining, using a 10mM citrate buffer, pH 6.0, for 10 minutes followed by cooling at room temperature for 20 min. Following antigen retrieval, incubate samples with primary antibody for 10 min at room temperature. A suggested positive control is breast carcinoma.
Human PgR exists in two forms: 116kDa (B-form) and 81kDa (A-form). Null mutation in PgR gene leads to pleiotrophic reproductive abnormalities. Expression of PgR has been suggested to predict better clinical response to endocrine therapy than ER alone. PgR is phosphorylated on multiple serine residues (at least seven sites) through distinct groups of sites coordinately regulated by hormone and different kinases.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
nuclear receptor subfamily 3 group C member 3; PgR
NR3C3; PGR; PR